Finding Value Left On The Shelf: Karuna Case Study

PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.  

Karuna logo
• Source: Shutterstock

PureTech Health plc's chief innovation and strategy officer, Eric Elenko, and president, Bharatt Chowrira, disclose details about the company's decision to develop a new schizophrenia therapy that could potentially alter the market – but can the model be repeated?

Founded by PureTech in 2009, Karuna Therapeutics, Inc. went public in 2019 and was acquired by Bristol Myers Squibb...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from C-Suite Speaks

More from Leadership